| Name | CYP2D6 |
|---|---|
| Synonyms | CPD 6; Xenobiotic monooxygenase; Microsomal monooxygenase; Flavoprotein linked monooxygenase; CPD6; CYP2D; CYP2D variant; CYP2D6… |
| Name | sulfuric acid |
|---|---|
| CAS | sulfuric acid |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 12485956 | Johnson K, Shah A, Jaw-Tsai S, Baxter J, Prakash C: Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers. Drug Metab Dispos. 2003 Jan;31(1):76-87. In contrast, direct conjugation of traxoprodil with glucuronic or sulfuric acid was the major pathway in PMs. |
4(0,0,0,4) | Details |
| 17315539 | Wu WN, McKown LA, Reitz AB: Metabolism of the new anxiolytic agent, a pyrido [1,2-] benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism. Eur J Drug Metab Pharmacokinet. 2006 Oct-Dec;31(4):277-83. The in vitro and in vivo metabolism of RWJ-53050, an anxiolytic agent, was investigated after incubation with rat and human hepatic S9 fractions, and human microsomes and 7 microsomes containing individual human CYP isoforms, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 in the presence of -generating system, and a single oral dose administration to dogs (30 mg/kg). |
2(0,0,0,2) | Details |
| 16035375 | Fuhr U, Kober S, Zaigler M, Mutschler E, Spahn-Langguth H: Rate-limiting biotransformation of is mediated by CYP1A2. . Int J Clin Pharmacol Ther. 2005 Jul;43(7):327-34. Mean inhibitor induced changes of 4'--TA formation were as follows: Furafylline 25 microM (CYP1A2), complete inhibition (-100%); 250 microM (CYP1A2 inhibitor/CYP2C 19 substrate), -30%; 25 microM (CYP2A6), -11%; quinidine 25 microM (CYP2D6), -9%; ketoconazole 25 microM (CYP3A), -18%; and erythromycin 250 microM (CYP3A), -8%. |
1(0,0,0,1) | Details |